First quarter 2023 results
First quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Featuring

Paul Hudson
Chief Executive Officer

Jean-Baptiste de Chatillon
Chief Financial Officer

Bill Sibold
Specialty Care

Olivier Charmeil
General Medicines

Dietmar Berger
Global Head of R&D ad interim

Thomas Triomphe
Vaccines

Julie van Ongevalle
Consumer Healthcare

Roy Papatheodorou
General Counsel
Highlights


We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. With two best in class launches this year and the acceleration of our early-mid stage pipeline, we are well underway.

Paul Hudson,
Chief Executive Officer